Helicobacter pylori and nonsteroidal anti-inflammatory drugs

Gastroenterology Clinics of North America

Volumn 30, Issue 4, 2001, Pages 937-952

  Chan, Francis K L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIULCER AGENT; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA BLOOD FLOW; STOMACH ULCER;

EID: 0035202237     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(05)70221-1     Document Type: Article

References (77)

1. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study
2. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa
3. Focal gastric mucosal blood flow at the site of aspirin-induced ulceration
4. Neutrophil-activating-peptide-I/Interleukin-8, a novel cytokine that activates neutrophils
5. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: Response to omeprazole dual therapy
6. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
7. Campylobacter-like organisms, non-steroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis
8. Prevention of recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking non-steroidal anti-inflammatory drugs
9. Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
10. Does eradication of H. pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study
11. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis
12. Screen-and-treat Helicobacter pylori to reduce the risk of peptic ulcers for patients starting long-term non-steroidal anti-inflammatory drug treatment - A double blinded randomized, placebo controlled trial
13. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa
14. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils
15. Peptic ulcer bleeding in the elderly: Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs
16. Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis
17. Nonsteroidal anti-inflammatory drug-induced dyspepsia - Is Campylobacter pyloridis implicated?
18. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic Multicentre Study
19. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH
20. Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: A meta-analysis
21. Gastric mucosal blood flow in misoprostol pretreated aspirin-induced ulceration
22. Effect of indomethacin and aspirin on gastric blood flow and acid secretion
23. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole
24. Prevalence of Helicobacter pylori infection and its effects on symptoms and nonsteroidal anti-inflammatory drug-induced gastro-intestinal damage in patients with rheumatoid arthritis
25. Long-term non-steroidal anti-inflammatory drug use and Helicobacter pylori infection
26. Effect of acid and pepsin on blood coagulation and platelet aggregation: A possible contributor to prolonged gastroduodenal mucosal hemorrhage
27. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
28. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs
29. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: Help NSAIDs study
30. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
31. Effect of indomethacin on gastric blood flow around acetic acid-induced gastric ulcers in rats
32. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroid anti-inflammatory drugs
33. The presence of Campylobacter pylori in nonsteroidal anti-inflammatory drug associated gastritis
34. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to nonsteroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis
35. Helicobacter pylori infection and the development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy
36. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation
37. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans
38. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
39. H. pylori eradication vs combined proton pump inhibitor and H. pylori eradication in the prevention of recurrent peptic ulcer complications in high-risk patients receiving low-dose aspirin
40. Interaction of NSAIDs and Helicobacter pylori on gastroduodenal injury and prostaglandin production: A controlled double-blind trial
41. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
42. Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats
43. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs
44. Aspirin can inhibit gastric mucosal cyclooxygenase without causing lesions in rat
45. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori
46. Campylobacter pylori, NSAIDs, and smoking: Risk factors for peptic ulcer disease
47. Do non-steroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection?
48. Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats
49. Role of inhibition of gastric mucous secretion in the phenomenon of gastric mucosal injury by indomethacin
50. Interactions of gastric blood flow, barrier breaker, and hydrogen ion back diffusion during ulcer formation in the rat
51. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer
52. Biochemical gastroprotection from acute ulceration induced by aspirin and related drugs
53. Relationship of gastric mucosal damage induced in pigs by anti-inflammatory drugs to their effects on prostaglandin production
54. Parenteral aspirin and sodium salicylate area equally injurious to the rat gastric mucosa
55. Helicobacter pylori infection in elderly people: Correlation between histology and serology
56. Helicobacter pylori is a protective factor for bleeding gastric ulcers but is not for bleeding duodenal ulcers in NSAID users
57. Effect of acetylsalicylic acid on gastric mucin activity, permeability to hydrogen ion, and susceptibility to pepsin
58. Evidence for weakening of gastric mucus integrity by Campylobacter pylori
59. H. pylori screening for individuals requiring chronic NSAID therapy: A decision analysis
60. Helicobacter pylori and nonsteroidal antirheumatics
61. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: Interaction with indomethacin
62. Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs
63. Aspirin-induced changes in gastric function: Role of endogenous prostaglandins and mucosal damage
64. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs - Influence of age, smoking, ulceration and Helicobacter pylori
65. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug users
66. Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of nonsteroidal anti-inflammatory drugs
67. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: Predisposition to ulceration and relation to Helicobacter pylori
68. Campylobacter pylori associated gastritis in patients taking non-steroidal anti-inflammatory drugs
69. Nonsteroidal anti-inflammatory drugs and gastropathy: The second hundred years
70. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process
71. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: Anti-inflammatory without gastropathy?
72. The mucoid cap over superficial gastric damage in the rat: A high-pH microenvironment dissipated by nonsteroidal anti-inflammatory drugs and endothelin
73. New insights into prostaglandins and mucosal defence
74. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat
75. Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator: Comparison with other monokines
76. Omeprazole compared with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs
77. Association of antral mucosal levels of interleukin 8 and reactive oxygen radicals in patients infected with Helicobacter pylori